(MedPage Today) — Oral nirmatrelvir-ritonavir (Paxlovid) failed to spare COVID-19-vaccinated individuals from the worst outcomes if they got sick, though it may have helped speed recovery time and cut viral loads, according to two community-based…
Source:
www.medpagetoday.com
Medical Disclaimer:
This content is shared for informational and educational purposes only.
It does not constitute medical, legal, or policy advice.
Healthcare decisions should always be made in consultation with qualified professionals.
